Amgen
US.AMGN
437.23
-6.89
-1.55%
Amgen
437.23
-6.89
-1.55%
Collector offline (last heartbeat: 19181s ago)
· 2026-09-04 19:59
Pre-market
438.95
-1.16%
After-hours
415.00
-5.08%
Overnight
442.22
-0.43%
Revenue annual, last 8 years
Latest year +9.95% YoY
Margins
- Gross margin
- 67.25%
- Operating margin
- 24.71%
- Net margin
- 20.98%
Key ratios & quality
- Enterprise value
- 281.86B
- PEG ratio
- 4.87
- Altman Z-Score
- 2.13
PEG uses trailing P/E against the 3-year net income growth rate (5.58%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.13, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 23.75B | 23.36B | 25.42B | 25.98B | 26.32B | 28.19B | 33.42B | 36.75B |
| Gross profit | 19.65B | 19.01B | 19.27B | 19.53B | 19.92B | 19.74B | 20.57B | 24.71B |
| Selling & admin expenses | 5.33B | 5.15B | 5.73B | 5.37B | 5.41B | 6.18B | 7.10B | 7.05B |
| Research & development | 3.74B | 4.12B | 4.21B | 6.32B | 4.43B | 4.78B | 5.96B | 7.27B |
| Operating profit | 10.26B | 9.67B | 9.14B | 7.64B | 9.57B | 7.90B | 7.26B | 9.08B |
| Pretax profit | 9.55B | 9.14B | 8.13B | 6.70B | 7.35B | 7.86B | 4.61B | 8.98B |
| Tax | 1.15B | 1.30B | 869.00M | 808.00M | 794.00M | 1.14B | 519.00M | 1.27B |
| Net profit | 8.39B | 7.84B | 7.26B | 5.89B | 6.55B | 6.72B | 4.09B | 7.71B |
| Basic EPS | 13 | 13 | 12 | 10 | 12 | 13 | 8 | 14 |
| Diluted EPS | 12.62 | 12.88 | 12.31 | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 8.15B | 9.18B | 9.56B | 9.87B | 8.62B | 10.05B |
| Gross profit | 5.18B | 6.17B | 6.48B | 6.89B | 5.87B | 7.24B |
| Selling & admin expenses | 1.69B | 1.69B | 1.72B | 1.95B | 1.60B | 1.75B |
| Research & development | 1.49B | 1.74B | 1.90B | 2.14B | 1.72B | 1.87B |
| Operating profit | 1.18B | 2.66B | 2.53B | 2.72B | 2.67B | 3.51B |
| Pretax profit | 1.97B | 1.57B | 3.92B | 1.51B | 2.08B | 2.77B |
| Tax | 243.00M | 136.00M | 705.00M | 181.00M | 265.00M | 393.00M |
| Net profit | 1.73B | 1.43B | 3.22B | 1.33B | 1.82B | 2.38B |
| Basic EPS | 3 | 3 | 6 | 2 | 3 | 4 |
| Diluted EPS | 3.20 | 2.65 | 5.93 | 2.45 | 3.34 | 4.37 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 37.62B | 18.44B | 21.14B | 19.39B | 22.19B | 30.33B | 29.03B | 29.06B |
| Cash & ST investments | 29.30B | 8.91B | 10.65B | 8.04B | 9.31B | 10.94B | 11.97B | 9.13B |
| Inventory | 2.94B | 3.58B | 3.89B | 4.09B | 4.93B | 9.52B | 7.00B | 6.23B |
| Total assets | 66.42B | 59.71B | 62.95B | 61.17B | 65.12B | 97.15B | 91.84B | 90.59B |
| Total current liabilities | 13.49B | 12.84B | 11.65B | 12.18B | 15.69B | 18.39B | 23.10B | 25.49B |
| Short-term debt | 4.42B | 2.95B | 91.00M | 87.00M | 1.59B | 1.44B | 3.55B | 4.60B |
| Long-term debt | 29.51B | 26.95B | 32.90B | 33.22B | 37.35B | 63.17B | 56.55B | 50.01B |
| Total liabilities | 53,916,000,000.00 | 50,034,000,000.00 | 53,539,000,000.00 | 54,465,000,000.00 | 61,460,000,000.00 | 90,922,000,000.00 | 85,962,000,000.00 | 81,928,000,000.00 |
| Total equity | 12.50B | 9.67B | 9.41B | 6.70B | 3.66B | 6.23B | 5.88B | 8.66B |
| Retained earnings | -17.98B | -21.33B | -21.41B | -24.60B | -28.62B | -26.55B | -27.59B | -25.11B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 26.93B | 26.73B | 27.89B | 29.06B | 31.48B | 34.96B |
| Cash & ST investments | 8.81B | 8.03B | 9.45B | 9.13B | 12.04B | 13.99B |
| Inventory | 6.73B | 6.58B | 6.35B | 6.23B | 6.19B | 6.22B |
| Total assets | 89.37B | 87.90B | 90.14B | 90.59B | 92.50B | 95.64B |
| Total current liabilities | 23.01B | 20.48B | 21.79B | 25.49B | 24.96B | 25.50B |
| Short-term debt | 3.37B | 2.44B | 2.15B | 4.60B | 5.44B | 5.45B |
| Long-term debt | 54.01B | 53.76B | 52.43B | 50.01B | 51.89B | 51.86B |
| Total liabilities | 83,160,000,000.00 | 80,469,000,000.00 | 80,522,000,000.00 | 81,928,000,000.00 | 83,314,000,000.00 | 83,951,000,000.00 |
| Total equity | 6.21B | 7.43B | 9.62B | 8.66B | 9.19B | 11.69B |
| Retained earnings | -27.14B | -25.71B | -23.80B | -25.11B | -24.65B | -22.28B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 11.30B | 9.15B | 10.50B | 9.26B | 9.72B | 8.47B | 11.49B | 9.96B |
| Depreciation & amortization | 1.95B | 2.21B | 3.60B | 3.40B | 3.42B | 4.07B | 5.59B | 5.17B |
| Free cash flow | 10.56B | 8.53B | 9.89B | 8.38B | 8.79B | 7.36B | 10.39B | 8.10B |
| Dividends paid | -3.51B | -3.51B | -3.76B | -4.01B | -4.20B | -4.56B | -4.83B | -5.12B |
| Stock buybacks / issuance | -17.79B | -7.70B | -3.49B | -4.98B | -6.36B | 0 | -200.00M | 0 |
| Ending cash balance | 6.95B | 6.04B | 6.27B | 7.99B | 7.63B | 10.94B | 11.97B | 9.13B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.39B | 2.28B | 4.68B | 1.60B | 2.19B | 4.00B |
| Depreciation & amortization | 1.39B | 1.34B | 1.31B | 1.13B | 1.12B | 1.11B |
| Free cash flow | 980.00M | 1.91B | 4.25B | 961.00M | 1.48B | 3.49B |
| Dividends paid | -1.28B | -1.28B | -1.28B | -1.28B | -1.36B | -1.36B |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 8.81B | 8.03B | 9.45B | 9.13B | 12.04B | 13.99B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE % | 44.48 | 70.73 | 76.13 | 73.16 | 126.47 | 135.79 | 67.55 | 106.10 |
| ROA % | 11.47 | 12.44 | 11.84 | 9.50 | 10.38 | 8.28 | 4.33 | 8.45 |
| ROIC % | 16.87 | 19.31 | 19.92 | 16.86 | 18.90 | 16.17 | 10.07 | 15.60 |
| 5-year avg ROE % | 25.13 | 34.96 | 45.04 | 54.34 | 78.20 | 96.46 | 95.82 | 101.82 |
| EBIT margin % | 46.06 | 44.63 | 36.95 | 30.40 | 33.25 | 38.06 | 23.23 | 31.92 |
| FCF / sales % | 44.46 | 36.52 | 38.90 | 32.26 | 33.37 | 26.11 | 31.10 | 22.04 |
| Current ratio | 2.79 | 1.44 | 1.81 | 1.59 | 1.41 | 1.65 | 1.26 | 1.14 |
| Quick ratio | 2.44 | 1.01 | 1.30 | 1.14 | 1.00 | 1.03 | 0.81 | 0.73 |
| Debt / assets | 271.43 | 309.14 | 350.58 | 497.15 | 1,063.78 | 1,036.79 | 1,022.61 | 630.68 |
| LT debt / equity | 236.08 | 278.61 | 349.61 | 495.85 | 1,020.32 | 1,013.64 | 962.21 | 577.56 |
| Interest coverage | 7.86 | 8.09 | 7.44 | 6.60 | 6.22 | 3.73 | 2.46 | 4.26 |
| Revenue CAGR (3Y) % | 3.11 | 0.54 | 3.62 | 3.04 | 4.06 | 3.50 | 8.76 | 11.77 |
| Net income CAGR (3Y) % | 6.55 | 0.52 | 54.26 | -11.12 | -5.81 | -2.58 | -11.46 | 5.58 |
| FCF CAGR (3Y) % | 4.94 | -3.91 | -2.02 | -7.41 | 0.98 | -9.38 | 7.44 | -2.67 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE % | 105.67 | 99.14 | 81.71 | 106.10 | 101.32 | 91.47 |
| ROA % | 6.51 | 7.40 | 7.74 | 8.45 | 8.58 | 9.53 |
| ROIC % | 13.06 | 13.98 | 14.27 | 15.60 | 15.54 | 16.60 |
| 5-year avg ROE % | -- | -- | -- | -- | -- | -- |
| EBIT margin % | 28.44 | 29.68 | 30.84 | 31.92 | 31.64 | 34.01 |
| FCF / sales % | 31.98 | 30.37 | 32.08 | 22.04 | 23.10 | 26.71 |
| Current ratio | 1.17 | 1.31 | 1.28 | 1.14 | 1.26 | 1.37 |
| Quick ratio | 0.74 | 0.82 | 0.82 | 0.73 | 0.85 | 0.95 |
| Debt / assets | 924.46 | 756.65 | 567.49 | 630.68 | 623.75 | 490.28 |
| LT debt / equity | 870.19 | 723.75 | 545.11 | 577.56 | 564.59 | 443.69 |
| Interest coverage | 3.18 | 3.53 | 3.89 | 4.26 | 4.38 | 4.86 |
| Revenue CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Other32.63%
Other products16.88%
Repatha9.48%
Prolia7.55%
EVENITY7.10%
Enbrel5.77%
TEPEZZA5.73%
Other revenues5.14%
Otezla4.88%
TEZSPIRE4.83%
Quote time 2026-09-04 19:59:10
For reference only, not investment advice.